Summary
Duchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
The global Duchenne Muscular Dystrophy market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.
Based on products type, the report describes major products type share of regional market. Products mentioned as follows:
Deflazacort
Prednisone
Others
Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows:
PTC Therapeutics
Sarepta Therapeutics
Bristol-Myers Squibb
ITALFARMACO
BioMarin
Daiichi Sankyo
Solid Biosciences
Summit Therapeutics
FibroGen
NS Pharma
Pfizer
ReveraGen BioPharma
Wave Life
Genethon
Santhera Pharmaceuticals
Based on Application, the report describes major application share of regional market. Application mentioned as follows:
Male
Female
Based on region, the report describes major regions market by products and application. Regions mentioned as follows:
Asia-Pacific
North America
Europe
South America
Middle East & Africa